LATTICEFLOW-AI
1.2.2024 14:01:33 CET | Business Wire | Press release
LatticeFlow AI, the leading Artificial Intelligence (AI) platform for enabling enterprises to build performant, safe, and trustworthy AI systems at scale, today announced the appointment of Tom Ulrich as Senior Vice President and General Manager for North America. More recently, Tom served as Vice President of Sales, Financial Services at C3.AI, where he played a key role in launching the company’s AI banking business which led to a successful IPO in 2019 (NYSE:AI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201601542/en/
(Graphic: Business Wire)
Tom’s appointment follows LatticeFlow AI’s strategic expansion into the US market. With over 25 years of experience, Tom has proven expertise in building and developing world class sales teams for high-growth enterprise SaaS companies.
“Tom brings unmatched expertise in scaling early to mid-stage tech companies into hyper-growth phases. At LatticeFlow AI, Tom will play a vital role in accelerating our growth trajectory by identifying strategic business opportunities and driving revenue growth in the North American market,” said Petar Tsankov, CEO & Co-founder of LatticeFlow AI.
Earlier in his career, Tom held various sales leadership roles at MicroStrategy, where he helped grow the company from $20 million to $500 million, culminating in a successful IPO (NASDAQ:MSTR). Throughout his professional journey, Tom has remained steadfast in his dedication to helping clients unlock business value through data-driven insights.
"As AI becomes increasingly integral in our daily lives, ensuring model trust, safety, and a positive societal impact is more important than ever. I’m excited and honored to join the LatticeFlow AI team, collaborating with some of the best AI engineers in the world who are focused on tackling these challenges. I look forward to helping our customers harness the power of AI, while accelerating model performance and safety,” said Tom Ulrich.
“Tom joining LatticeFlow AI serves as yet another testimonial to the Company’s ability to attract world-class talent,” stated Andre Boisvert, Chairman of LatticeFlow AI. “Tom’s extensive experience in building global sales teams across five distinct enterprise software companies, with a particular focus on predictive analytics and AI, underscores his invaluable potential for propelling LatticeFlow AI's advancement.”
Tom received an MBA from George Washington University with a major in International Business and is based in Vienna, VA.
About LatticeFlow AI
Founded by world renowned AI researchers from ETH Zurich, LatticeFlow AI enables enterprise companies to develop production-ready machine learning models at scale. By systematically identifying and fixing model and data issues at scale, we help enterprises unlock the true potential of AI. Additionally, we offer a comprehensive technical AI assessment to assist enterprises achieve regulatory compliance, reliability and robustness for their mission-critical AI applications. LatticeFlow AI has won several awards including the AI Privacy Challenge in April 2023, followed by the Swiss AI Award and the US Army Global AI Award.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201601542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom